Perspective - (2022) Volume 8, Issue 2

Metformin is the First Line Drug for the Treatment of Type 2 Diabetes
Klaudia Sztyler*
Department of Chemistry, University of Hamburg, Germany
*Correspondence: Klaudia Sztyler, Department of Chemistry, University of Hamburg, Germany, Email:

Received: 30-Mar-2022, Manuscript No. JBCC-22-63662; Editor assigned: 01-Apr-2022, Pre QC No. JBCC-22-63662; Reviewed: 15-Apr-2022, QC No. JBCC-22-63662; Revised: 22-Apr-2022, Manuscript No. JBCC-22-63662; Published: 29-Apr-2022


Considerable efforts had been made because the Nineteen Fifties to higher apprehend the mobile and molecular mechanisms of motion of metformin, an amazing antihyperglycemic agent now endorsed because the first line oral remedy for kind 2 diabetes (T2D). The fundamental impact of this drug from the biguanide own circle of relatives is to acutely lower hepatic glucose production, mainly via a moderate and brief inhibition of the mitochondrial respiratory-chain complicated. In addition, the ensuing lower in hepatic strength fame turns on the AMPactivated protein kinase (AMPK), a mobile metabolic sensor, offering a typically widespread mechanism for metformin motion on hepatic gluconeogenic program. The demonstration that the respiratory-chain complicated, however now no longer AMPK, is the number one goal of metformin became these days reinforced via way of means of displaying that the metabolic impact of the drug is preserved in liver-precise AMPK-poor mice. Beyond its impact on glucose metabolism, metformin became suggested to repair ovarian characteristic in polycystic ovary syndrome, lessen fatty liver and to decrease micro vascular and macro vascular headaches related to T2D. Its use became additionally these days recommended as an adjuvant remedy for most cancers or gestational diabetes, and for the prevention in pre-diabetic populations. Prevalence of kind 2 diabetes (T2D) has reached epidemic proportions global and promotes the danger for cardiovascular illnesses and early mortality. Prevention and control of T2D has turn out to be a primary public fitness venture across the world. Metformin (1,1-dimethylbiguanide), a biguanide derivate, is the maximum extensively prescribed drug to deal with hyperglycemia in people with T2D and is endorsed, alongside life-style modification (diet, weight manage and bodily activity), as a primary line oral remedy alongside within side the current tips of the American Diabetes Association and European Association of the Study of Diabetes . This advice became primarily based totally on scientific research as the United Kingdom Prospective Diabetes Study (UKPDS), a multi-centre randomized managed path of various treatment plans for T2D. This landmark take a look at suggested that in depth glucose manage with metformin seems to lower the danger of diabetes-associated endpoints and dying in obese diabetic patients, and is related to much less weight benefit and less hypoglycaemic assaults whilst in comparison to insulin and sulphonylureas.

Metformin is presently the drug of first desire for the remedy of T2D, being prescribed to at the least a hundred and twenty million humans worldwide. Metformin is appeared as an antihyperglycemic agent as it lowers blood glucose concentrations in T2D without inflicting overt hypoglycemia. Metformin is likewise regularly defined as an insulin sensitizer main to discount in insulin resistance and giant discount of plasma fasting insulin level. The development in insulin sensitivity through metformin can be ascribed to its fine outcomes on insulin receptor expression and tyrosine kinase activity. Metformin may exert its useful metabolic moves in element via the modulation of a couple of additives of the incretin axis. Maida et al. have certainly currently said that metformin acutely will increase plasma tiers of glucagon-like peptide 1 (GLP-1) and induces islet incretin receptor gene expression via a mechanism this is depending on peroxisome proliferator-activated receptor (PPAR)-α. However, a developing frame of proof from scientific research and animal fashions shows that the number one feature of metformin is to lower hepatic glucose production, particularly through inhibiting gluconeogenesis.


Although the molecular goal of metformin changed into elusive for numerous years, Zhou et al. said that the activation of AMP-activated protein kinase (AMPK) changed into in detail related to the pleiotropic moves of metformin. AMPK is a phylogenetically conserved serine/ threonine protein kinase considered as a gas gauge tracking systemic and cell power fame and which performs a vital position in shielding cell features beneath power-constrained conditions. AMPK is a heterotrimeric protein which includes a catalytic α-subunit and regulatory subunits β and γ and every subunit has at the least isoforms.


The Author expresses his gratitude to the entire faculty for successful publication of this article.

Conflict of Interest

The Author declared that there is no conflict of interest.

Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Get the App